Mauna Kea Technologies (ALMKT) Corporate presentation summary

Platform and market

• Cellvizio delivers real-time cellular imaging during procedures; its platform has 20+ FDA 510(k) clearances, 1,200+ peer-reviewed publications and 200+ patents.

• Revenue model combines system sales with recurring probe sales and pay-per-use; probes support 10–20 procedures each.

• Estimated annual procedure revenue opportunity is $1bn in the U.S. and an additional ~$1bn internationally across pancreatic cysts, Barrett’s esophagus and food intolerance.

Pancreatic cyst lesions

• CLIMB enrolled 526 patients across 14 U.S. centers; adding EUS-nCLE raised diagnostic accuracy from 73% to 85%, with >40% fewer unnecessary surgeries for benign cysts and ~6x fewer missed cancers.

• Dedicated CPT code 43252 and ESGE guideline inclusion support adoption; hospital reimbursement is $3,939 with Cellvizio versus $1,960 without.

• DDW consortium attendance rose from 15 in 2023 to 110 in 2026; 25 Cellvizio abstracts were accepted for DDW 2026.

• TaeWoong Medical partnership pairs Cellvizio imaging with EUS-guided radiofrequency ablation; 100+ U.S. centers already have EUS-RFA equipment.

Barrett’s esophagus

• Cellvizio-assisted imaging detected 2.4x more Barrett’s cases and 243% more dysplasia than standard random-biopsy approaches; reported sensitivity was 96% and specificity 93%.

• A Korea National HTA agency meta-analysis of 33 studies and 2,350 patients found ~3x dysplasia detection, 48.5% fewer biopsies per patient and 89% pooled sensitivity for esophageal and gastric neoplasia.

• CPT 43252 reimbursement adds $1,497 per hospital procedure and $645 per ASC procedure versus diagnostic EGD; 2026 rates rose while EGD-only rates fell.